Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	37.08	36.33	26.29	30.78	109.28	52.25
Short-Term Investments	75.63	86.29	99.72	116.14	46.04	71.02
Cash & Short-Term Investments	112.71	122.62	126	146.91	155.32	123.27
Cash Growth	-12.79%	-2.68%	-14.23%	-5.41%	26.00%	35.71%
Accounts Receivable	1.18	2.41	1.78	1.35	0.9	1.31
Other Receivables	0.2	0.3	0.6	-	-	-
Receivables	1.38	2.71	2.38	1.35	0.9	1.31
Prepaid Expenses	2.72	1.98	3.65	2.87	4.45	3.12
Total Current Assets	116.81	127.32	132.03	151.14	160.66	127.7
Property, Plant & Equipment	0.17	4.36	6.09	6.81	8.08	9.33
Long-Term Investments	-	-	6.28	37.36	35.69	-
Other Long-Term Assets	0.03	0.03	-	0.1	0.06	0.04
Total Assets	117.01	131.71	144.4	195.42	204.49	137.08
Accounts Payable	2.24	2.32	3.22	3.52	3.17	2.99
Accrued Expenses	3.9	5.25	7.05	12.51	7.66	6.16
Current Portion of Leases	0.56	0.48	0.43	0.37	0.38	0.39
Current Unearned Revenue	6.76	7.57	11.79	16.46	-	-
Other Current Liabilities	5.97	-	-	-	-	-
Total Current Liabilities	19.43	15.62	22.49	32.86	11.22	9.54
Long-Term Debt	4.41	4.83	6.95	10.37	16.3	19.55
Long-Term Leases	0.63	0.81	1.34	1.82	2.23	2.59
Long-Term Unearned Revenue	2.86	2.86	-	6	-	-
Other Long-Term Liabilities	10.52	10.23	7.6	7.53	5.3	3.43
Total Liabilities	37.85	34.34	38.38	58.57	35.05	35.11
Common Stock	1,416	1,410	1,350	1,319	1,287	985.94
Additional Paid-In Capital	82.09	82.05	81.27	72.41	65.49	60.75
Retained Earnings	-1,371	-1,347	-1,277	-1,204	-1,134	-1,046
Comprehensive Income & Other	-48.17	-48.14	-48.42	-50.49	-48.34	-48.17
Total Common Equity	79.16	97.37	106.02	136.85	169.44	-47.44
Shareholders' Equity	79.16	97.37	106.02	136.85	169.44	101.97
Total Liabilities & Equity	117.01	131.71	144.4	195.42	204.49	137.08
Total Debt	5.6	6.12	8.72	12.55	18.91	22.54
Net Cash (Debt)	107.11	116.51	123.57	171.72	172.1	100.73
Net Cash Growth	-17.51%	-5.71%	-28.04%	-0.22%	70.85%	47.09%
Net Cash Per Share	0.57	0.63	0.74	1.14	1.62	1.33
Filing Date Shares Outstanding	191.53	191.48	179.49	162.57	148.64	95.58
Total Common Shares Outstanding	191.48	189.96	169.87	157.46	144.99	89.68
Working Capital	97.38	111.7	109.54	118.28	149.44	118.16
Book Value Per Share	0.41	0.51	0.62	0.87	1.17	-0.53
Tangible Book Value	79.16	97.37	106.02	136.85	169.44	-47.44
Tangible Book Value Per Share	0.41	0.51	0.62	0.87	1.17	-0.53
Machinery	-	7.72	7.98	7.28	6.79	5.99
Leasehold Improvements	-	8.59	8.59	8.59	8.56	8.56

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q